Both are expressed in breast and ovarian cancer and other epithelial malignancies [29,30]. children and episodes of mastitis. Among controls, prior mastitis was associated with significantly higher anti-CA15.3 and anti-CA125 antibody levels and, among cases, with significantly lower preoperative CA125 levels. Conclusion Puerperal that mastitis may produce long-lasting anti-mucin antibodies that may lower the risk for ovarian cancer, plausibly through Rabbit Polyclonal to MINPP1 enhanced immune surveillance. Studying immune reactions related to MUC1 and MUC16 in the 10C20% of breastfeeding women Chlorzoxazone who develop mastitis may suggest ways to duplicate its effects through vaccines based on both antigens. Keywords: CA125, CA15.3, Ovarian Cancer, Puerperal Mastitis INTRODUCTION An estimated 22,280 women in the U.S. were diagnosed with and 15,500 died of ovarian cancer in 2012 [1]. Prevention will require a comprehensive understanding of risk factors for this deadly disease and underlying mechanisms. Ages at menarche and menopause, births, and lengths of breastfeeding and oral contraceptive use (OC) are important reproductive eventsoften aggregated to estimate number of ovulatory cycles which are directly correlated with ovarian cancer risk [2]. Less easily explained by ovulation, events like hysterectomy (without oophorectomy) and tubal ligation lower ovarian cancer risk and endometriosis and genital talc use increase it [3,4,5]. To explain these associations, we hypothesized that they alter ovarian cancer risk through effects related to the mucin (MUC) family of cell surface glycoproteins, especially MUC1, or CA15.3, which is over-expressed in many cancers including ovarian. Acute events, like hysterectomy or tubal ligation, release a tumor-like form of MUC1 and elicit anti-MUC1 antibodies which signal enhanced immune surveillance, thereby reducing ovarian cancer risk [6]. Conversely chronic events, such as repeated ovulations, lead to more continuous exposure to MUC1, dampen mucin-specific immunity, and produce immune tolerance of an emerging MUC1+ cancer. Key elements of this model were confirmed in prospective data from the Nurses Health Study [7]. Two protective events we considered were puerperal mastitis and mumps parotitis. Regarding mastitis, we presented limited case-control data showing mastitis may Chlorzoxazone lower ovarian cancer risk [6]. Regarding mumps, we reviewed epidemiologic evidence that mumps reduced risk for ovarian cancer and showed that individuals going through a mumps infection do, in fact, have elevated levels of anti-MUC1 antibodies as well as elevated levels of CA125, or MUC16 [8]. In this report, we present new case-control data on the association between mastitis and ovarian cancer and examine plasma anti-MUC1 and anti-MUC16 antibody levels as possible biomarkers of an immune surveillance mechanism for ovarian cancer risk reduction. METHODS Study Design and Population Data for this study arose from the last two enrollment periods of a case-control study of ovarian cancer in New England (period 4 (1998C2002) and period 5 (2003C2008)) described elsewhere [9]. Briefly, 2,877 women residing in eastern Massachusetts and New Hampshire with a diagnosis of ovarian cancer were identified through hospital tumor boards and statewide cancer registries. Of these 2,206 (77%) were eligible and 1,588 (72%) agreed Chlorzoxazone to participate (1,483 epithelial and 105 non-epithelial ovarian cancers). 4,366 controls were identified through a combination of drivers license and town resident lists, 2,940 (67%) were eligible, 1,362 (46%) declined to participate and 1,578 (54%) were enrolled. Controls were frequency matched to cases on age and state of residence. After written informed consent, demographic information, reproductive and medical history, and habits were assessed by in-person interviews. Approximately 95% of cases and controls provided a blood sample at the time of the interview. Pathology reports were reviewed for histologic type, grade,.